Rabin Medical Center

Yonalink launches Israel Clinical Trials Network (ICTN) to establish Israel as a leader in clinical trial research, supported by the Israel Innovation Authority and Ministry of Health. ICTN aims to attract global pharmaceutical and medical device companies, leveraging Israel's digitized healthcare system and robust innovation ecosystem. Participating hospitals include Sheba Medical Center, Rabin Medical Center, and Hadassah Medical Center.

Can-Fite BioPharma announces first patient dosing in Phase IIa pancreatic cancer trial, evaluating Namodenoson's safety and clinical activity.

The Israeli Genome Project, or Mosaic, aims to create a national clinical genetic database from 100,000 Israelis, with a budget of 250 million shekels. Currently, only Clalit members can participate, and nearly 50,000 samples have been collected. The project seeks to leverage Israel's genetic diversity for medical advancements and economic benefits, offering genomic data to local research institutions at a subsidized rate.